Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $32.80, for a total value of $492,000.00. Following the completion of the sale, the chief executive officer owned 657,540 shares of the company’s stock, valued at $21,567,312. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cameron Turtle also recently made the following trade(s):

• On Friday, January 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $30.68, for a total value of $460,200.00.
• On Monday, December 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $29.02, for a total value of $435,300.00.

Spyre Therapeutics Trading Down 3.7%

Shares of NASDAQ:SYRE opened at $32.07 on Thursday. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $35.31. The company has a market cap of $2.49 billion, a PE ratio of -14.64 and a beta of 3.15. The stock has a 50 day moving average of $32.52 and a 200 day moving average of $23.76.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.53. Equities research analysts predict that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Spyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SYRE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Spyre Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company’s stock worth $442,000 after buying an additional 4,277 shares during the last quarter. CWM LLC raised its position in Spyre Therapeutics by 357.8% during the second quarter. CWM LLC now owns 1,712 shares of the company’s stock valued at $26,000 after purchasing an additional 1,338 shares during the period. TD Asset Management Inc raised its position in Spyre Therapeutics by 409.5% during the second quarter. TD Asset Management Inc now owns 113,968 shares of the company’s stock valued at $1,706,000 after purchasing an additional 91,600 shares during the period. AlphaQuest LLC boosted its stake in Spyre Therapeutics by 30.8% during the second quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock worth $62,000 after buying an additional 983 shares during the period. Finally, Emerald Advisers LLC boosted its stake in Spyre Therapeutics by 3.3% during the second quarter. Emerald Advisers LLC now owns 565,863 shares of the company’s stock worth $8,471,000 after buying an additional 18,036 shares during the period. 80.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SYRE shares. Citigroup started coverage on Spyre Therapeutics in a research note on Wednesday, December 17th. They set a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Jones Trading upgraded shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Monday, December 1st. Mizuho raised shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $70.00 price target on shares of Spyre Therapeutics in a research note on Friday, January 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Spyre Therapeutics presently has an average rating of “Buy” and a consensus price target of $53.88.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.